Asad Haider

as you think about doing -- building a broader portfolio around 295, just what might that look like in the context of Rob's earlier comments

how you see the oncology portfolio evolving from here. With respect to novel combos

Just curious as to what your latest thinking is on business development. You've always referenced BD priorities that are geared towards the 2030s

Just one bigger picture question on the oncology franchise, maybe for Roopal. You've mentioned that you're watching the PD-1 VEGF class

how do the timing of these readouts impact the company's BD strategy as you think about the different outcomes

just given how consequential the clinical readouts at the end of this year are going to be for the company

Do you believe you're still on track for the 30% to 40% patient conversion by 2028

Any updated thoughts on the shape of this over the next couple of years in the context of the potential R&D expenses associated with the development of BNT327

Could you share with us any early thoughts on the pipeline and if there are programs that you're particularly encouraged by

remind us on how we should be thinking about the read across from that trial to ADEPT-1 and ADEPT-4 in 2026

updated thoughts on costs and margins as it relates to your goal of shortening the depth of earnings

what's driving this renewed emphasis on BD? If you could unpack that a little bit more

any updated views on what you see as the key product variances versus the Street looking towards the end of the decade

if you could just maybe double click a little bit more on what the key levers are to bridge to that double-digit growth profile from where we sit today

can you just maybe double-click a little bit more on how you're going to be balancing capital allocation priorities?

do you have sufficient capacity today to manufacture for the U.S. market in the U.S.

Are you able to provide any quantitative framing on your views as it relates to the extent to which you think this erosion gets smoothed

What's your level of confidence on that launch curve framing in the context of the early experience

can you just talk about what you're seeing in the contracting environment broadly speaking across the incretin portfolio

what are the learnings from this for the orforglipron ramp next year as it relates to the elasticity of demand across different price points

Where do you think this could stabilize? And how is that segment changing the landscape on pricing?

what is your expectation on market share dynamics in the next weeks and months from the CVS formulary loss?

where you still see the biggest gaps in your portfolio that could benefit from more BD as you scan the therapeutic landscape

any updated framing on what you're looking for would be helpful

speak to your level of confidence on the demand dynamics from that channel in the current environment

what innings are we in in terms of just portfolio pruning or realignment, noting that you've also recently announced a new reorganization

what could cause large swings to those expectations from here?

can you just double click on how competitive dynamics are playing out in that market relative to your own expectations?

can you remind us the timelines on when we will start to see more data?